Safety of intravenous immune globulin in an outpatient setting for patients with neuromuscular disease.
Muscle Nerve
; 60(5): 528-537, 2019 11.
Article
em En
| MEDLINE
| ID: mdl-31443119
ABSTRACT
INTRODUCTION:
Although intravenous immune globulin (IVIg) is used to treat patients in the outpatient setting, there is limited documentation addressing the safety of this practice.METHODS:
Retrospective analysis of 438 patients with neuromuscular diseases receiving IVIg in an outpatient setting.RESULTS:
Adverse events (AE) overall occurred in 16.9% of patients. Headache was the most common AE, noted in 11.6% of patients. Serious AEs occurred in 0.91% of patients; aseptic meningitis was the only one noted. Multivariate analyses identified the following risk factors for AEs first-lifetime course of IVIg, higher dose per course of IVIg, diagnosis of myasthenia gravis, women, and younger age.DISCUSSION:
Intravenous immune globulin is generally safe to administer in an outpatient setting. Women, myasthenia gravis patients, and those receiving their first course or a higher total dose of IVIg are at an increased risk of experiencing an AE.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Imunoglobulinas Intravenosas
/
Fatores Imunológicos
/
Doenças Neuromusculares
Tipo de estudo:
Etiology_studies
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limite:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Muscle Nerve
Ano de publicação:
2019
Tipo de documento:
Article